[Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction]

The problem of chronic prostatitis (CP) and erectile dysfunction (ED) involves not only their high prevalence, but also the insufficient effectiveness of their treatments. In this regard, there is need for administration the pathogenetic drugs with antihypoxic, antioxidant and neuroprotective effects and improving blood flow to the genitals. The study included 60 men with CP associated with ED, aged 22 to 60 years. Patients were randomized into 2 groups of 30 people. Patients of comparison group received baseline therapy (alpha1-adrenoblockers, non-specific anti-inflammatory drugs, digital prostate massage and vacuum phallostimulation). Antibiotics were applied on the basis of their potential effectiveness in chronic abacterial prostatitis. In addition to the above treatment, patients of main group received step-down therapy with cytoflavin (in infusion, then oral administration). Positive dynamics was noted in both groups of patients; however, according to the indicators of the severity of pain and dysuria, as well as quality of life, positive dynamics in the main group of patients was more significant. Similarly, the dynamics of objective criteria for inflammation in the prostate gland was more pronounced when using cytoflavin. After treatment, the rigid phase of erection during vacuum fallotest occurred within 2-3 min from the beginning of the procedure in 16 (53.3%) patients of main group and only in 9 (30%) patients of comparison group. During follow-up examination at 6 months after treatment, stable remission was found in 75% of patients of main group. Thus, the inclusion of cytoflavin in the scheme of complex treatment of patients with abacterial CP associated with ED is pathogenetically justified, makes it more efficient and provides good DFS.

[Treatment of erectile dysfunction in patients with chronic prostatitis using vibromagnetic lazer]

The study was aimed to evaluation of the effectiveness of vibromagnitic lazer therapy (VMLT) of erectile dysfunction (ED) in patients with chronic prostatitis (CP). The study included 40 patients with CP, aged 22 to 45 years. CP duration ranged from 6 months to 9 years, ED--from 6 months to 7 years. All the patients underwent a survey on "Chart of sexological examination of man" with the calculation of sex constitution index, an transrectal ultrasonography of prostate gland (PG), uroflowmetry, clinical and functional assessment of components of the copulatory interval, and assessment of blood plasma concentrations of peptide and steroid hormones. All patients underwent a psychotherapeutic correction of sexual disadaptation, sex therapy using Masters-Johnson, Kaplan, and Lo Piccolo methods, and VMLT using "Matrix-Urologist" device. The control group included 20 healthy men aged 22 to 45 years. All studies were performed Before and 30 days after the end of the last VMLT session. As a result of the treatment, integral IIEF indicators were normalized in 60% of patients, the volume of the prostate--in 70%, hemodynamics in the phase of relaxation and erection--in 70%, venous blood flow in the PG--in 70%, dorsal artery hemodynamics in the phase of relaxation and erection--in 60%, and penile hemodynamics--in 60% of patients. Voiding bladder function was optimized in 75% of patients. The functional activity of the pituitary-adrenal-testicular system returned to normal level in 60% of patients. 1 year after treatment, sexual function was maintained at attained levels in 47.5% of patients. As a matter of findings, it was concluded that VMLT is high effective method of combined non-pharmacological correction of erectile dysfunction in CP patients with strong and medium sex constitution.

[Efficacy of compound xuanju capsule on type-III prostatitis-related sexual dysfunction]

OBJECTIVE

To investigate the value of Compound Xuanju Capsule in the treatment of type-III prostatitis-related sexual dysfunction.

METHODS

We randomly divided 90 type-III prostatitis patients with sexual dysfunction diagnosed by NIH clinical criteria into an experiment group and a control group to be treated with Compound Xuanju Capsule and antibiotics, respectively. We analyzed the therapeutic results based on the scores on chronic prostatitis symptom index (CPSI), prostatitis-related sexual function index (PSFI ) and self-rating anxiety scale (SAS), and compared them between the two groups and with the baseline data.

RESULTS

The degree of prostatitis-related sexual dysfunction was not correlated with that of prostatitis symptoms. Prostatitis symptoms and sexual function were significantly improved in the experiment group than in the control (P < 0.05), and the SAS score was markedly lower in the former than in the latter (P < 0.05).

CONCLUSION

Compound Xuanju Capsule can not only alleviate the symptoms of type-III prostatitis, but also improve its related sexual dysfunction and anxiety.

Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International Index of Erectile Function-5 questionnaires

OBJECTIVE

The aim of this study is to assess the association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) using the Core Lower Urinary Tract Symptom Score (CLSS) and the International Index of Erectile Dysfunction (IIEF)-5 questionnaires.

METHODS

A total of 220 consecutive treatment-naive men completed the International Prostate Symptom Score (IPSS), CLSS, and IIEF-5 questionnaires. The clinical diagnoses were benign prostate hyperplasia (BPH, n=58), prostatic cancer (n=51), prostatitis (n=28), overactive bladder wet (OAB wet, n=16), other diagnoses (n=39), and controls (n=28). Simple statistics and predictability of low IIEF-5 score were examined.

RESULTS

The total IIEF-5 score significantly correlated with both the IPSS and CLSS questionnaires (p=0.0001). Among IPSS and CLSS symptoms, factors other than daytime frequency and incomplete emptying showed significant correlation with the total IIEF-5 score. A multivariate regression model indicated nocturia and urethral pain as independent factors for low IIEF-5 scores.

CONCLUSION

Urethral pain was identified as an independent factor for erectile dysfunction. The extraction of pain symptoms using CLSS questionnaire may be useful to evaluate LUTS in men with pelvic health problems.

Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation

INTRODUCTION

Chronic benign prostate diseases are very common and certainly feature significantly in urological practice.The treatment of chronic benign prostate diseases is a common problem in clinical practice: few studies have been conducted in routine clinical practice to evaluate the efficacy of the treatments for this clinical condition. The objective of this study was to evaluate the efficacy of an extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms (LUTS) in patients with chronic benign prostate diseases with associated inflammation, also taking into consideration the influence of treatment on sexual function and, therefore, on patients' quality of life.

MATERIALS AND METHODS

All the 591 eligible subjects were evaluated on entering the study; after a screening visit, including medical history, physical examination, physical examination and digital rectal examination (DRE) and laboratory tests, the patients underwent uroflowmetry. The subjects under investigation were also asked to complete the IPSS, NIH-CPSI and IIEF-5 questionnaires, for the purpose of evaluating urinary symptoms and erectile function in relation to sexual activity in the previous 6 months.

RESULTS

The analysis of the uroflowmetry results showed that treatment with extract of Serenoa repens distinctly improves bladder voiding and lower urinary tract symptoms, as highlighted also by the improvement in the scores for the IPSS and NIH-CPSI questionnaires which serve as a basis for evaluating the urinary symptoms of patients with prostatic hyperplasia and chronic prostatitis respectively. The results also suggest that using an extract of Serenoa repens for 6 months in patients with chronic benign prostate diseases gives rise to an improvement in erectile function, as demonstrated by the increase in the scores for the IIEF-5 questionnaire after 6 months of treatment.

CONCLUSIONS

The results of this study demonstrate how treatment for 6 months with an extract of Serenoa repens in routine clinical practice gives rise to a statistically significant improvement in Qmax values and in the IPSS, NHI-CPSI and IIEF-5 questionnaire scores, resulting not only in an improvement in urinary symptoms but also in an overall improvement in patients' quality of life.

[Prostagut forte treatment of patients with prostatic adenoma with comorbid chronic prostatitis]

The study consisting of four visits included 69 patients with prostatic adenoma and concomitant chronic prostatitis. The patients received either monotherapy with an alpha adrenoblocker or combined treatment including phytodrug prostagut forte. The results of the study showed that the above combined treatment produces more pronounced and persistent improvement of urodynamic indices, leads to reduction of leukocyte count in the urine and prostatic secretion, upgrades quality of life. The absence of side effects allows recommendation of prostagut forte for treatment of presenile and senile patients with prostatic adenoma and associated pathology.

[Treatment of chronic prostatitis in prophylaxis of prostatic adenoma]

The results of a retrospective study of efficacy of prostamol uno in a standard single dose of 320 mg/day in prevention of chronic prostatitis recurrences and prostatic adenoma used for 5 years as an adjuvant to standard therapy of chronic prostatitis exacerbations were compared with those of standard course antibacterial and anti-inflammatory treatment alone. The analysis demonstrated that prostamol uno (Serenoa repens extract) in a dose 320 mg/day improves both subjective symptoms (data of IPSS, QoL scale) and objective ones (the absence of the disease progression and adverse effects, enhancement of the erectile function). Prostamol uno is effective for prevention of both recurrences of chronic prostatitis exacerbations and development of prostatic adenoma.

[Nutrition of patients with stomach acid-dependent pathology and inflammatory diseases of the urogenital system]

In work some, often meeting nosological forms urogenithal surgical diseases which last years frequently proceed against gastritises, stomach ulcer of a stomach and 12-perstnoj guts owing to increase of occurrence of the last are presented. For treatment various medicamentous schemes, which do-polnjajutsja rational diet-correction for the purpose of increase efficaci and qualities of treatment are used. The work purpose--to present features ratsional pathogenetic correctic a food at persons from an aggravation acid-deprndent to a pathology against constant reception prepara apropos urogenithal diseases.

Self-reported spousal support modifies the negative impact of pain on disability in men with chronic prostatitis/chronic pelvic pain syndrome

OBJECTIVES

To examine changes in the association between pain and patient quality of life (QoL), depressive symptoms, and disability in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) at varying levels of spouse responses to pain.

MATERIAL AND METHODS

One-hundred eighty-eight men with CP/CPPS completed a questionnaire, including demographic information. The outcome variables were mental QoL (SF-12 MCS), physical QoL (SF-12 PCS), depressive symptoms (Center for Epidemiological Studies Depression Scale), and disability (Pain Disability Index). Patients also reported on the types of responses they had from their spouses (Multidimensional Pain Inventory), and pain (Short-Form McGill Pain Questionnaire).

RESULTS

The association between pain and disability was stronger at higher levels of solicitous responses (eg, "Does some of my chores") (β = 0.66, P <.05) than it was at moderate (β = 0.44, P <.05) and lower (β = 0.23, ns) levels. In contrast, the association between pain and disability was stronger at lower levels (β = 0.64, P <.05) of distracting responses (eg, "Tries to get me involved in some activity") than it was at moderate (β = 0.44, P <.05) and higher (β = 0.25, P <.05) levels.

CONCLUSIONS

Solicitous responses to pain increased the negative impact of pain on disability, whereas distracting responses to pain decreased the negative impact of pain on disability in men with CP/CPPS. Solicitous responses may be a reaction to patient pain and associated disability, or may help create or maintain the patient's pain and disability. In either case, distracting rather than solicitous responses to patient pain are to be encouraged in symptom management.

Use of acupuncture as a treatment method for chronic prostatitis/chronic pelvic pain syndromes

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is the most common category of clinical prostatitis. The etiologic factors of CP/CPPS still remain unknown, and standard therapies often fail to achieve sustainable amelioration of symptoms; therefore, various treatment therapies have been approached. Recently, there is increasing evidence that acupuncture could be a safe and effective treatment in managing CP/CPPS. However, acupuncture therapy still is ranked as low-priority treatment, which results from the fact that the studies, mostly reported in nontraditional medical journals, had not employed standard definitions of the condition or validated-outcome parameters, and that the mechanism of acupuncture effects on CP/CPPS remains to be elucidated. In this article, we review the recent clinical research using acupuncture to reveal its clinical utility for CP/CPPS and the possible mechanisms of action. This article could encourage health care providers and urologists to apply acupuncture for managing pains of CP/CPPS with standard treatment.

Hypertrophic-congestive and fibro-sclerotic ultrasound variants of male accessory gland infection have different sperm output

INTRODUCTION

Male accessory gland infection (MAGI) exerts a negative influence on male fertility which depends upon its extension. Indeed, we have shown that patients with MAGI involving prostate, seminal vesicles and epididymis have worse sperm parameters compared with patients with prostatitis alone or prostate-vesiculitis. Similarly, MAGI extending bilaterally is associated with a worse sperm output. The aims of this study were to evaluate the prevalence of two different additional ultrasound (US) findings (hypertrophic- congestive and a fibro-sclerotic US form) and to evaluate their semen quality.

MATERIALS AND METHODS

One hundred infertile patients with MAGI, diagnosed according to the World Health Organization (WHO) 1993 criteria, were evaluated by scrotal and transrectal ultrasound scans. The control group consisted of 100 healthy, age-matched men.

RESULTS

The ultrasound examination confirms two separate US variants of MAGI: a hypertrophic-congestive (prevalence of 56%) and a fibro-sclerotic form (prevalence of 29%). Patients with hypertrophic-congestive MAGI showed higher sperm concentration, motility and normal forms, but also higher sperm leukocytes concentration and seminal reactive oxygen species compared to patients with fibro-sclerotic MAGI. However, all these parameters were significantly worse than those observed in the control group.

DISCUSSION

Infertile patients with hypertrophic-congestive MAGI have a better sperm quality compared with patients with fibrosclerotic MAGI; however, they showed higher oxidative stress in semen.

[Correction of erectile dysfunction in patients with chronic abacterial prostatitis]

A total of 76 patients with chronic abacterial prostatitis (CAP) in combination with erectile dysfunction were divided into two groups. Clinical symptoms of CAP and severity of erectile dysfunction were the same in both groups. Patients of the study group (n = 36) received pathogenetic treatment (vitaprost plus physiotherapy) and impase. The control group (n = 40) received vitaprost and physiotherapy. The results of the treatment showed that impase addition to combined treatment of CAP patients with erectile dysfunction significantly improves erectile function: 80.6% patients given impase raised their score by International Index of Erectile Function Scale to normal (26 points and higher). Impase efficacy increased with prolongation of the treatment from 4 to 12 weeks.

[Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis]

OBJECTIVE

To investigate the relationship between vitamin D receptor (VDR) gene Fok I polymorphisms and BPH complicated by histological prostatitis (BPH + HP).

METHODS

We detected Fok I polymorphisms in the peripheral blood of 79 patients with BPH + HP and 81 controls with BPH only using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and analyzed the frequency distribution of the genotypes and alleles of the two groups of patients.

RESULTS

Obvious differences were found in the distribution of genotypes and alleles between the BPH + HP patients (FF: 27% [21/79], Ff: 30% [24/79], ff: 43% [34/79]) and the controls (FF: 33% [27/81], Ff: 36% [29/81], ff: 31% [25/81]), with statistical significance in the distribution of the genotype ff (P < 0.05). The histological prostatitis group showed a significant difference from the controls in the frequency of the f allele (58% [196/338] vs 49% [153/312], P < 0.05), but not in that of the F allele (42% [142/338] vs 51% [159/312] , P > 0.05).

CONCLUSION

VDR Fok I polymorphisms may be correlated with BPH complicated by histological prostatitis.

[Expressions of integrinalpha2beta1 and CD133 in benign prostatic hyperplasia complicated by prostatitis and their significance]

OBJECTIVE

To study the expressions of Integrinalpha2beta1 and CD133 in benign prostatic hyperplasia (BPH) complicated by prostatitis and their significance.

METHODS

Specimens were obtained from 56 BPH patients undergoing transvesical prostatectomy. Paraffin sections of the specimens were subjected to HE staining for pathological examination of inflammatory changes under the light microscope. Twenty-four patients with simple BPH were included in Group A, and the other 32 with BPH complicated with prostatitis in Group B. The expressions of Integrinalpha2beta1 and CD133 in the prostatic tissues of the two groups were determined by immunohistochemistry, Western blotting and IPP6.0 image analysis software.

RESULTS

The expressions of Integrinalpha2beta1 and CD133 were significantly higher in Group B than in A (P < 0.05), and so were the mean relative value of the optical density of Integrinalpha2beta1 (0.29 +/- 0.18 vs 0.04 +/- 0.03) and that of CD133 (0.08 +/- 0.07 vs 0.0020 +/- 0.0018) (P < 0.05).

CONCLUSION

Inflammation can up-regulate the expressions of Integrinalpha2beta1 and CD133 in BPH tissue.

[Correction of immunometabolic disorders in chronic bacterial prostatitis]

Patients with chronic bacterial prostatitis were found to have disorders in blood parameters of complement system activity, neutrophil function and metabolic status. The above disorders are resistant to adequate correction with standard treatment but can be successfully managed with combined use ofimmunomodulators (ferrovir, galavit), antioxidants (mexidol, olifen) and membranoprotectors (phosphogliv, essentiale). Thus, immunometabolic status in chronic prostatitis can be corrected with the above combined treatment.

[Selzink plus study in patients with chronic non-infectious prostatitis and abnormal fertility]

Correction of subnormal spermatogenesis caused by chronic prostatitis is made with application of different therapeutic schemes. Our aim was to investigate efficacy of selzink medicine which corrects deficiency of trace elements Se and Zn in ejaculate and thus improves spermatogenesis. One-month course of therapy produced no side effects, had a positive effect on low fertility of ejaculate. Therefore, selzink can be recommended in combined treatment of male infertility.

[The relationship between anaphylatoxin C3a and benign prostatic hyperplasia with inflammation]

OBJECTIVE

To study the relationship of anaphylatoxin C3a level in expressed prostatic secretions (EPS) with prostate tissue inflammation in BPH.

METHODS

This study included 40 BPH patients receiving TURP operational therapy in West China Hospital during September, 2009 to March, 2010. For each patient, IPSS and NIH-CPSI were evaluated, serum PSA levels, prostatic volume and urine WBC were measured. EPS was collected before operation for the test of C3a level, while EPS also was obtained from 10 healthy men as normal control. Prostatic tissue was collected by the operation and histological inflammation was investigated by histopathological study.

RESULTS

C3a levels in EPS of the BPH patients: severe inflammation group > mild inflammation group > normal control group (all P < 0.01). C3a levels in the EPS could be used to determine whether BPH combined inflammation, sensitivity : 0.97, specificity: 0.70. C3a levels in EPS was not relevant with PSA, fPSA levels, age, BMI, prostate volume or urine WBC levels; but NIH-CPSI was correlated (r = 0.495, P < 0.01). C3a in EPS of retained catheter group was more than non-catheter group significantly (P < 0.05).

CONCLUSION

C3a is an ideal criteria to diagnose prostatic histological inflammation in BPH patients. There is no convincing evidence to correlate C3a in EPS with serum PSA levels, BMI, age, prostatic volume and urine's WBC. Excessively high C3a levels and the NIH-CPSI, indwelling have correlations.

Clinicopathological association between BPH and prostatitis

This was a prospective study done in Nepal Medical College Teaching Hospital, Kathmandu, Nepal to find out the relationship between BPH and BPH associated with prostatitis as regards their symptoms and histopathology. We looked at the symptoms of both disease processes and tried to establish whether we could differentiate between the two entities on a clinical basis. Our study included thirty six patients who were operated for symptoms suggestive of LUTS due to BPH. Prior to the operation they were asked about their symptoms and we correlated these for the two conditions. We analysed the results of the symptoms statistically according to the odd's ratio. We found that the most common symptom associated with BPH with prostatitis was dysuria, however, there was a lot of overlap of the symptoms. So unless there is a high degree of suspicion on the part of the health care worker it is difficult to make a diagnosis of prostatitis based on symptoms alone and it is difficult to distinguish between the two conditions. The histopathological specimens were analysed and it was found that 19 of the 36 patients had prostatitis associated with BPH. This was done by scrutinising the received histopathological specimens. Here it was found that the most common type of prostatitis associated with BPH was the stromal inflammatory pattern.

Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin

INTRODUCTION

This pilot study determined the efficacy of rifaximin, a gut-directed antibiotic, in reducing chronic prostatitis (CP) and gastrointestinal (GI) symptoms in patients with CP type III. The prevalence of small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) in patients with CP was also evaluated.

MATERIALS AND METHODS

Chronic prostatitis patients were recruited and screened for SIBO and IBS using the lactulose breath test (LBT) and Rome II criteria, respectively. Patients with a positive LBT result and Chronic Prostatitis Symptom Index (CPSI) score ≥ 15 received rifaximin 550 mg three times daily for 10 days. The CPSI score and global improvement of CP and GI symptoms were ascertained at screening (ie, 7 days before therapy), at baseline immediately before therapy (ie, day 0), and on days 14 and 28.

RESULTS

Fourteen of 16 CP patients (88%) had a positive LBT result and were included in this therapeutic study (mean age, 41 years). Mean CPSI score significantly decreased from screening to day 28 (ie, 18 days after rifaximin treatment; p = 0.043). Mean abdominal pain and bloating scores were also significantly reduced on day 28 versus baseline (p = 0.010 and p = 0.003, respectively). Chronic prostatitis patients with IBS and SIBO had a statistically significant response as well.

CONCLUSION

Data from this pilot study suggest that SIBO and IBS are common in CP and that patients with CP and SIBO may benefit from rifaximin therapy. Further studies are warranted.

High frequency of chronic bacterial and non-inflammatory prostatitis in infertile patients with prostatitis syndrome plus irritable bowel syndrome

BACKGROUND

Although prostatitis syndrome (PS) and irritable bowel syndrome (IBS) are common disorders, information on the prevalence of IBS in infertile patients with PS is relatively scanty. Therefore, this study was undertaken to estimate the frequency of PS and IBS and to evaluate the prevalence of the various diagnostic categories of prostatitis.

METHODOLOGY/PRINCIPAL FINDINGS

This study enrolled 152 patients with PS, diagnosed by the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) in an andrological setting, and 204 patients with IBS, diagnosed according to the Rome III diagnostic criteria in a gastroenterological setting. The patients with PS were asked to fulfill the Rome III questionnaire for IBS, whereas patients with IBS were asked to complete the NIH-CPSI. The simultaneous presence of PS and IBS was observed in 30.2% and 31.8% of the patients screened by andrologists and gastroenterologists, respectively. Altogether, 111 patients had PS plus IBS (31.2%). They had a total NIH-CPSI and pain subscale scores significantly higher than patients with PS alone. Gastrointestinal symptoms in patients with PS plus IBS were similar to those reported by patients with IBS alone and significantly greater in patients with PS alone. Patients with PS plus IBS had a significantly higher frequency of chronic bacterial prostatitis (category II) and lower of non-inflammatory prostatitis (category IIIB), compared to patients with PS alone. The frequency of inflammatory prostatitis (category IIIA) resulted similar.

CONCLUSIONS/SIGNIFICANCE

Prostatitis syndromes and IBS are frequently associated in patients with PS- or IBS-related symptoms. These patients have an increased prevalence of chronic bacterial and non-inflammatory prostatitis.

[Efficacy of combined physiotherapeutic methods in complex treatment of patients with chronic infectious urethroprostatitis]

The study is aimed at investigation of efficacy and safety of a combined effect of laser therapy and vibromagnetotherapy in complex treatment of patients with chronic urethroprostatitis in the presence of sexually transmitted infection (STI). A total of 35 males aged 20 to 51 years entered the study. They were divided into 3 groups. Group 1 received standard basic therapy, group 2 received basic and laser therapy, group 3 - basic treatment and laser plus vibromagnetotherapy. Effectiveness of the treatment was assessed by the evidence obtained from clinical, bacteriological, device and functional examinations. The results of the treatments were evaluated after 2 weeks of the follow-up. It is shown that patients of groups 2 and 3 achieved more pronounced improvement of clinical and laboratory indices, parameters of basal blood flow. Thus, physiotherapy, added to antibacterial treatment, is safe and effective in the treatment of chronic urethroprostatitis and STI.

[Treatment of prostatic adenoma with concomitant chronic bacterial prostatitis]

A randomized trial of efficacy and safety of vitaprost plus and vitaprost forte has been made in 70 patients with prostatic adenoma comorbid with chronic bacterial prostatitis. The patients were randomized into two groups: group 1 patients received vitaprost plus in rectal suppositoria for 1 months, then vitaprost forte for 2 months; group 2 patients (control) received gentos and lomefloxacin per os. Short- and long-term results were evaluated in 3 and 6 months. By all parameters group 1 achieved better treatment results than controls. Immediate positive response was observed in 97.1% patients, long-term positive effects were observed in 85.7%. Total points of prostatic adenoma symptoms reduced by 37%, chronic prostatitis--by 55%, residual urine diminished by 66%, Qmax increased, quality of life improved by 45%, sexual function enhanced. Size of the prostate decreased by 7.4 cm3, leukocyte count in prostatic secretion fell 6-fold, eradication of prostatitis causing agent was achieved in 3 months in 80% patients. Side effects and complications were not registered. Thus, vitaprost plus and vitaprost forte are highly effective and safe for treatment of patients with combination of prostatic adenoma with chronic bacterial prostatitis.

[Structural and functional characteristics of erythrocytes, endothelial dysfunction and lipid peroxidation in patients with prostatic adenoma and comorbid chronic prostatitis]

Patients with prostatic adenoma combined with chronic prostatitis were found to have abnormal content of proteins in peripheral blood erythrocytic membrane, erythrocytic sorption, concentration of nitric oxide stable metabolites, endotheline-1 and lipid peroxidation products in blood plasma before and after transurethral resection of the prostate. Different dosage forms of the drug longidase were tested for efficacy in correction of impairment of structural and functional properties of erythrocytes, endothelial dysfunction and lipid peroxidation in the above patients.